MiNK Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	-3.8	689.6
Revenue growth		-100.0%	-100.6%
Cost of goods sold	0.0	0.0	0.0	19,146.1
Gross profit	0.0	0.0	-3.8	-18,456.4
Gross margin			100.0%	-2676.3%
Selling, general and administrative [+]			1.3	3,828.0
General and administrative	0.0	0.0	1.3	3,828.0
Research and development			9.5
EBITDA [+]			-14.6	-22,247.7
EBITDA growth		-100.0%	-99.9%
EBITDA margin			379.7%	-3226.0%
Depreciation and amortization			0.1	36.8
EBIT [+]	0.0	0.0	-14.6	-22,284.5
EBIT growth		-100.0%	-99.9%
EBIT margin			381.1%	-3231.4%
Interest expense			2.4	1,560.9
Interest expense			2.4	1,560.9
Other income (expense), net [+]	-28.0	-30.2	0.8	43.2
Gain (loss) on foreign currency transactions				269.2
Other			0.8	-43.2
Pre-tax income	-28.0	-30.2	-16.2	-23,802.2
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-28.0	-30.2	-16.2	-23,802.2
Net margin			422.8%	-3451.5%

Basic EPS [+]	($0.83)	($1.16)	($0.67)	($0.99)
Growth	-28.4%	72.3%	-31.9%
Diluted EPS [+]	($0.83)	($1.16)	($0.67)	($0.99)
Growth	-28.4%	72.3%	-31.9%

Shares outstanding (basic) [+]	33.7	26.0	24.1	24,059.0
Growth	29.4%	8.0%	-99.9%
Shares outstanding (diluted) [+]	33.7	26.0	24.1	24,059.0
Growth	29.4%	8.0%	-99.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.